Press releases

15 August, 2016

Regulatory

NeuroVive completes 10 percent acquisition of Isomerase Therapeutics

Lund, Sweden, August 15, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the second step in the previously announced ...

9 August, 2016

Regulatory

NeuroVive’s novel strategy for treatment of mitochondrial disease published in Nature Communications

Lund, Sweden, August 9, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that research results from the NVP015 program inve ...

6 July, 2016

Regulatory

NeuroVive announces Arbutus Biopharma’s notice of termination

Lund, Sweden, July 6, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that Arbutus Biopharma (formerly OnCore Biopharma, I ...

7 June, 2016

Regulatory

NeuroVive announces CiPRICS study completes enrolment

Lund, Sweden, 7 June 2016 - NeuroVive Pharmaceutical AB (publ), announces that the CiPRICS (Ciclosporin to Protect Renal function In Cardiac Surgery) clinical research team at the Department of Cardio ...

2 June, 2016

Regulatory

NeuroVive share upgraded to OTC Markets Group – OTCQX Best Market in the US

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has announced that the company's share has been upgraded to trading on the OTC Market Group's best market, OTCQX in the US. The ...

31 May, 2016

Regulatory

NeuroVive Pharmaceutical AB (publ) – amendment number of shares and votes

Pursuant to chapter 4, § 9 of the Swedish Financial Instruments Trading Act (1991:980), the company is hereby reporting that as a result of new share issue conducted by NeuroVive Pharmaceutical AB (pu ...

31 May, 2016

Regulatory

NeuroVive: Interim Report 1 Jan. 2016 to 31 Mar. 2016

Full speed ahead First Quarter (1 Jan. 2016 – 31 Mar. 2016)Net revenues were SEK 0 (0) and other operating income was SEK 46,000 (49,000).Loss before tax was SEK 10,916,000 […]

23 May, 2016

Regulatory

Updated timeline for conversion of NeuroVive’s BTUs into shares and warrants

NeuroVive Pharmaceutical AB (publ) announces that registration of the preferential rights issue totaling SEK 94.4 m has now been completed, and provides an updated timeline for the conversion of Neuro ...

10 May, 2016

Regulatory

NeuroVive preferential rights issue fully subscribed

NeuroVive Pharmaceutical AB (publ) has completed the preferential rights issue of units, comprising shares and warrants, authorized by the Extraordinary General Meeting on 31 March 2016. The preferent ...

29 April, 2016

Regulatory

NeuroVive Pharmaceutical AB (publ): Report from AGM

NeuroVive Pharmaceutical AB (publ) held its Annual General Meeting (AGM) yesterday, 28 April 2016. A summary of the resolutions follows. All resolutions were passed with the required majority.

28 April, 2016

Regulatory

NeuroVive’s R&D Team to Present Research Progress at Mitochondrial Medicine Conference

NeuroVive Pharmaceutical AB (publ), the pioneers in mitochondrial medicine, will present important research findings together with researchers at Lund University in three scientific poster presentatio ...

26 April, 2016

Regulatory

NeuroVive insiders and employees intend to subscribe for a minimum of 5.4 million SEK

NeuroVive Pharmaceutical AB (publ) announces that board members, other insiders and employees intend to subscribe for a minimum of 129 000 units, equivalent to at least SEK 5.4 million, in the company ...